Axsome Therapeutics Inc
Closed
SectorHealthcare
244.35 1.67
Overview
Share price change
24h
Min
241.93
Max
244.92
Income | -36M -65M |
|---|---|
Sales | -4.8M 191M |
EPS | -1.26 |
Profit margin | -33.756 |
Employees | 1,220 |
EBITDA | -36M -61M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +9.16% upside |
Next Earnings | 3 Aug 2026 |
|---|
Market Cap | 2.8B 12B |
|---|---|
Previous open | 242.68 |
Previous close | 244.35 |
Axsome Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Axsome Therapeutics Inc Forecast
Price Target
By TipRanks
9.16% upside
12 Months Forecast
Average 266.69 USD 9.16%
High 310 USD
Low 200 USD
Based on 17 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
